File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users - A randomized trial

TitleLansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users - A randomized trial
Authors
Issue Date2003
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APT
Citation
Alimentary Pharmacology And Therapeutics, 2003, v. 18 n. 8, p. 829-836 How to Cite?
AbstractAim: To study whether prophylaxis with lansoprazole could prevent relapse of ulcers after eradication of Helicobacter pylori in patients with NSAID-related peptic ulcers. Methods: Patients who presented with peptic ulcers and were found to be infected with H. pylori while receiving NSAIDs were recruited into the study. They received, twice daily, lansoprazole 30 mg, amoxicillin 1 g and clarithromycin 500 mg for 1 week, followed by lansoprazole 30 mg daily for 4 weeks. Patients with healed ulcers and H. pylori eradicated were given naproxen 750 mg daily, and randomly assigned to receive lansoprazole 30 mg daily or no treatment for 8 weeks. The primary endpoint was the cumulative recurrence of symptomatic and complicated ulcers. Results: At the end of the 8-week treatment period, significantly fewer patients (1/22, 4.5%, 95% confidence interval [CI] 0-23) in the lansoprazole group compared with the group that received H. pylori eradication alone (9/21, 42.9%, 95% CI 22-66) developed recurrence of symptomatic and complicated ulcers (log rank test P = 0.0025). Conclusions: Lansoprazole significantly reduced the cumulative relapse of symptomatic and complicated ulcers in patients requiring NSAIDs after eradication of H. pylori.
Persistent Identifierhttp://hdl.handle.net/10722/162767
ISSN
2015 Impact Factor: 6.32
2015 SCImago Journal Rankings: 2.833
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLai, KCen_US
dc.contributor.authorLam, SKen_US
dc.contributor.authorChu, KMen_US
dc.contributor.authorHui, WMen_US
dc.contributor.authorKwok, KFen_US
dc.contributor.authorWong, BCYen_US
dc.contributor.authorHu, HCen_US
dc.contributor.authorWong, WMen_US
dc.contributor.authorChan, OOen_US
dc.contributor.authorChan, CKen_US
dc.date.accessioned2012-09-05T05:23:15Z-
dc.date.available2012-09-05T05:23:15Z-
dc.date.issued2003en_US
dc.identifier.citationAlimentary Pharmacology And Therapeutics, 2003, v. 18 n. 8, p. 829-836en_US
dc.identifier.issn0269-2813en_US
dc.identifier.urihttp://hdl.handle.net/10722/162767-
dc.description.abstractAim: To study whether prophylaxis with lansoprazole could prevent relapse of ulcers after eradication of Helicobacter pylori in patients with NSAID-related peptic ulcers. Methods: Patients who presented with peptic ulcers and were found to be infected with H. pylori while receiving NSAIDs were recruited into the study. They received, twice daily, lansoprazole 30 mg, amoxicillin 1 g and clarithromycin 500 mg for 1 week, followed by lansoprazole 30 mg daily for 4 weeks. Patients with healed ulcers and H. pylori eradicated were given naproxen 750 mg daily, and randomly assigned to receive lansoprazole 30 mg daily or no treatment for 8 weeks. The primary endpoint was the cumulative recurrence of symptomatic and complicated ulcers. Results: At the end of the 8-week treatment period, significantly fewer patients (1/22, 4.5%, 95% confidence interval [CI] 0-23) in the lansoprazole group compared with the group that received H. pylori eradication alone (9/21, 42.9%, 95% CI 22-66) developed recurrence of symptomatic and complicated ulcers (log rank test P = 0.0025). Conclusions: Lansoprazole significantly reduced the cumulative relapse of symptomatic and complicated ulcers in patients requiring NSAIDs after eradication of H. pylori.en_US
dc.languageengen_US
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APTen_US
dc.relation.ispartofAlimentary Pharmacology and Therapeuticsen_US
dc.rightsAlimentary Pharmacology and Therapeutics. Copyright © Blackwell Publishing Ltd.-
dc.subject.mesh2-Pyridinylmethylsulfinylbenzimidazolesen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 And Overen_US
dc.subject.meshAmoxicillin - Therapeutic Useen_US
dc.subject.meshAnti-Bacterial Agents - Therapeutic Useen_US
dc.subject.meshAnti-Inflammatory Agents, Non-Steroidal - Adverse Effectsen_US
dc.subject.meshAnti-Ulcer Agents - Therapeutic Useen_US
dc.subject.meshClarithromycin - Therapeutic Useen_US
dc.subject.meshDyspepsia - Etiologyen_US
dc.subject.meshEndoscopy, Gastrointestinalen_US
dc.subject.meshFemaleen_US
dc.subject.meshFollow-Up Studiesen_US
dc.subject.meshHelicobacter Infections - Drug Therapyen_US
dc.subject.meshHelicobacter Pylorien_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshOmeprazole - Analogs & Derivatives - Therapeutic Useen_US
dc.subject.meshPatient Complianceen_US
dc.subject.meshPeptic Ulcer - Chemically Induced - Drug Therapyen_US
dc.subject.meshRecurrence - Prevention & Controlen_US
dc.subject.meshTreatment Outcomeen_US
dc.titleLansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users - A randomized trialen_US
dc.typeArticleen_US
dc.identifier.emailChu, KM:chukm@hkucc.hku.hken_US
dc.identifier.emailWong, BCY:bcywong@hku.hken_US
dc.identifier.authorityChu, KM=rp00435en_US
dc.identifier.authorityWong, BCY=rp00429en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1046/j.1365-2036.2003.01762.xen_US
dc.identifier.pmid14535877-
dc.identifier.scopuseid_2-s2.0-10744223126en_US
dc.identifier.hkuros86433-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-10744223126&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume18en_US
dc.identifier.issue8en_US
dc.identifier.spage829en_US
dc.identifier.epage836en_US
dc.identifier.isiWOS:000185840700010-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridLai, KC=7402135595en_US
dc.identifier.scopusauthoridLam, SK=7402279473en_US
dc.identifier.scopusauthoridChu, KM=7402453538en_US
dc.identifier.scopusauthoridHui, WM=7103196477en_US
dc.identifier.scopusauthoridKwok, KF=7102194177en_US
dc.identifier.scopusauthoridWong, BCY=7402023340en_US
dc.identifier.scopusauthoridHu, HC=36812244900en_US
dc.identifier.scopusauthoridWong, WM=7403972413en_US
dc.identifier.scopusauthoridChan, OO=7403167965en_US
dc.identifier.scopusauthoridChan, CK=7404813960en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats